The global single-use bioreactors market size was valued at USD 2.21 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 17.0% from 2021 to 2028. Increasing adoption of single-use bioreactors among small companies and startups, technological advancements in single-use bioreactors, and advantages offered by these products are key factors driving the market. Furthermore, despite the global COVID-19 pandemic, the market for SUBs has witnessed a significant increase in revenue. Many biopharmaceutical companies are in the race to develop an effective vaccine against the SARS-CoV-2 virus. This has resulted in increased demand for single-use bioreactors. For instance, ABEC has provided six 4,000 L single-use bioreactors to the Serum Institute of India for the large-scale production of COVID-19 vaccines at reasonable costs.
According to several survey results, the adoption of SUBs is registering a growth rate of 11% on annual basis. With fluctuating demand for biopharmaceuticals, the scope of stainless-steel bioreactors and accompanying large capital expenses have become a challenge. SUBs have successfully addressed traditional bioreactors-associated challenges with their flexibility to serve the growing demand for biopharmaceuticals. Flexibility is recognized as one of the key industry factors to drive investment in single-use bioreactor technology.
Furthermore, the rising demand for highly potent therapeutics worldwide, which does not require a large number of bioreactors, is anticipated to accelerate the adoption of disposable bioreactors in the coming years. Small-scale, bench-top SUBs provide a faster turnaround time by minimizing the need for assembling, cleaning, and autoclaving. These reactors are considered as workhorses for process development and optimization, consequently driving the implementation of SUBs for biopharmaceutical development.
Moreover, SUBs hold the potential to reduce the cost associated with conventional bioreactors. Implementation costs of disposable bioreactors tend to be much lower than conventional stainless-steel bioreactor systems. Hence, the adoption of these products can be mainly attributed to the cost-saving advantages in terms of construction, operating, and cleaning. Purchasing considerations in selecting single-use bioreactors are cost, desired operating volume, reaction size, temperature control, and capacity.
The single-use bioreactor systems segment accounted for the largest revenue share of over 80.0% in 2020. Single-use bioreactor systems have gained widespread acceptance in current biopharmaceutical manufacturing methods focusing on high product yield. The flexibility, cost-effectivity, and high mass production offered by single-use bioreactors will enhance the demand, thereby impacting the growth.
Such advantages will result in the demand for rapid development, increased manufacturing of new biotherapeutics such as vaccines, antibodies, enzymes, and hormones, and an increase in the quantities of products that can be reached in these bioreactors, thus contributing to the market growth. Furthermore, the rising focus of key players for providing small-scale bioreactors will boost the segment growth for the coming years.
The availability of disposable bioprocess bags in various sizes for a number of applications such as storage of cell cultures, buffers, sterile media, sera, and reagents is anticipated to propel market growth. Single-use media bags enhance manufacturing reproducibility by offering strength, temperature resistance, and durability.
Stirred tank bioreactors captured the largest revenue share of over 80.0% in 2020. The advantages offered by these bioreactors such as good oxygen transfer and fluid mixing ability, low operating costs, easy scale-up, compliance with cGMP requirements, and alternative impellers have led to the highest penetration of stirred tank bioreactors in the market.
Furthermore, increasing adoption of stirred tank SUBs from pilot-scale to large-scale manufacturing is anticipated to boost the market growth in the coming years. Flexible scaling capabilities have aided in meeting current production demands. With the changing market needs, the scale of SUB can also be adjusted, in turn, reducing costly capacity excess or drug shortages.
Moreover, the rising provision of wave-induced single-use bioreactors will boost market growth in the near future. Wave Biotech AG is offering the original wave bioreactor BIOSTAT RM for the last 10 years and in 2019, the company introduced the 2nd generation, BIOSTAT RM II with advanced features and improved temperature control and drive system. Such advancements by the manufacturers will drive the market for wave-induced single-use bioreactors in the forecast period.
The mammalian cells segment accounted for the largest share of over 80.0% in 2020. This can be attributed to the high penetration of these cells in biopharmaceutical therapeutics development and the commercial success of mammalian cell-derived recombinant proteins. According to BioProcess International, 85% of biopharmaceutical candidates that are under clinical development are produced in mammalian cell cultures.
Furthermore, mammalian cell cultivation for the production of recombinant proteins has rapidly promoted its application in clinical settings. Out of 62 recently approved biopharmaceutical recombinant proteins, 52 were produced from mammalian cell cultures. Moreover, the growing usage of single-use bioreactors for mammalian cell culture in various research studies is another major factor expected to impact the market growth significantly in the coming years.
Yeasts are a well-established eukaryotic host for heterologous protein production and provide unique advantages in the manufacturing of therapeutic recombinants. The rising focus of various research institutes and scientists for understanding the applicability of yeast cells in clinical or therapeutic settings will expedite the market growth in the forecast period. For instance, research issued by the NCBI in June 2021 reviewed the advanced methods and strategies for heterologous pharmaceutical protein synthesis using yeast genes.
The vaccines segment dominated the market in 2020 with a revenue share of over 25.0%. This is majorly due to the global outbreak of the SARS-CoV-2 virus resulting in an urgent need for an effective vaccine against the virus. As per BioPlan Associates’ report on COVID-19 Impact on Bioprocessing, the adoption of single-use systems in commercial manufacturing is expected to rapidly increase. In response to the current pandemic, a substantial number of biopharmaceutical companies are actively engaged in the rapid development of COVID-19 vaccines.
These programs are majorly based on single-use bioreactors as these systems are flexible, cost-effective, and reduce the risk of cross-contamination. Amid the COVID-19 pandemic, single-use systems are expected to be employed by major stakeholders in the biopharmaceutical market. Such a continuous increase in the adoption of single-use systems is anticipated to drive the market.
Furthermore, expanding landscape of cell and gene therapies is expected to boost the adoption of SUBs in this segment. In January 2021, Sartorius collaborated with RoosterBio, Inc. to enhance gene and cell therapy manufacturing capabilities. The collaboration is aimed at scaling up the production of regenerative medicine. Sartorius is one of the key players in the market for single-use bioreactors.
In 2020, the research and development (R&D)/process development segment captured the largest revenue share of over 75.0%. The adoption of single-use bioreactors in process development is an expediting factor for market growth. For instance, as per the article published by the American Pharmaceutical Review in 2020, around 71.2% of single-use bioreactors have been used in the industry for process development.
Furthermore, single-use systems are engaged in every aspect of the bioprocess industry. It is estimated in the American Pharmaceutical Review that around 85% of operations are carried out by single-use system devices for clinical or process development. This indicates the dominance of single-use bioreactors in research & development and clinical manufacturing.
Owing to the several advantages offered by SUBs, the bioproduction segment is anticipated to witness the growing adoption of these bioreactors in the near future. Significant advancements in bioreactor designs, film technologies, sensor systems, and stirring mechanisms have contributed to the growing use of disposable reactors on a large scale, from the lab to the factory.
The lab-scale production segment accounted for the largest revenue share of over 35.0% in 2020. Disposable bioreactors are widely used in preclinical and clinical research in the biopharmaceutical industry. Increasing adoption of single-use technology in cell therapy-based research and vaccine production is expected to have a significant impact on the segment growth.
The large-scale production segment is anticipated to witness significant growth throughout the forecast period. This is attributed to the rapidly growing demand for the commercial production of biopharmaceutical products and the expansion of manufacturing capabilities to meet the demand. For instance, in February 2021, Wuxi Biologics launched a 36,000L biomanufacturing line using nine 4,000L single-use bioreactors.
The CMOs and CROs segment accounted for the largest revenue share of over 35.0% in 2020. The demand for more flexible production capacity and quick campaign change-overs is high among CMOs. As a result, they tend to use a wider range of single-use components and systems. With the increasing trend of outsourcing, CMOs and CROs are more likely to adopt SUBs.
This trend is attributed to the efficiency of SUBs and ease of use while dealing with multiple biopharmaceutical products and changing market demands. Such factors result in significant penetration of SUS devices and faster adoption of new SUS technologies among CMOs. CMOs’ ever-changing processing facilities and lines and the more stable product developers for bioprocessing equipment and facilities are driving the segment.
Pharmaceutical and biopharmaceutical companies are anticipated to witness lucrative growth opportunities during the forecast period. It is estimated that 66% of biopharmaceutical companies have adopted disposable bioreactors in their workflows. Strategic collaborations between product manufacturers and biopharmaceutical companies also supplemented the market growth. For instance, in July 2021, BioCentriq and Pall Corporation collaborated for the clinical manufacturing of Zolgensma - the FDA-approved gene therapy using iCELLis fixed bed bioreactor.
North America captured the largest revenue share of over 30.0% in 2020. This is attributed to the presence of major operating players and a well-established biopharmaceutical industry in the region. In addition, the expansion of manufacturing capabilities in the region has supplemented the market growth. For instance, In September 2021, Thermo Fisher Scientific announced its plans to establish a new manufacturing facility dedicated to single-use bioprocessing products. The addition of the Nashville site expanded its global network of SUT manufacturing sites.
Evolving landscape pertaining to manufacturing and bioprocessing is a major factor for the market growth in the U.S. In December 2020, Cytiva opened a new manufacturing facility for Xcellerex XDR single-use bioreactors in the U.S. in collaboration with Biomedical Advanced Research and Development Authority. It is a part of the company’s USD 500 million plan to expand global manufacturing for the next five years.
Asia Pacific is projected to register the fastest CAGR throughout the forecast period. It is estimated that about 50 % of the new bioprocessing facilities across the globe are being established by Asian companies, including domestic players and international giants. This is expected to majorly drive the Asia Pacific market in the near future. China is expected to be at the forefront owing to the high adoption of single-use technology in the country.
The market is rapidly emerging and is expected to witness increasing market competition in the coming years. The growing trend of implementing disposable bioreactors has resulted in the increasing number of new market entrants, in turn intensifying the market competition. The key market players are undertaking various strategic initiatives to maintain their market presence. New product launches, mergers and acquisitions, and capacity expansion are some of the key strategies implemented by the key market participants. Sartorius AG is one of the leading market players owing to its broad product portfolio for single-use bioreactors.
For instance, in March 2021, Thermo Fisher Scientific introduced HyPerforma DynaDrive single-use bioreactors with a capacity of 3,000 L and 5,000 L. This launch was aimed to meet the strong demand for large-scale single-use bioprocessing. Some prominent players in the global single-use bioreactors market include:
Sartorius Stedim Biotech
Thermo Fisher Scientific
Celltainer Biotech BV
PBS Biotech Inc.
Able Corporation & Biott Corporation
G&G Technologies Inc.
Solida Biotech GmbH
Satake Chemical Equipment Mfg., Ltd.
Stobbe Pharma GmbH
Market size value in 2021
USD 2.73 billion
Revenue forecast in 2028
USD 7.76 billion
CAGR of 17.0% from 2021 to 2028
Base year for estimation
2017 - 2019
2021 - 2028
Revenue in USD million/billion and CAGR from 2021 to 2028
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, type, type of cell, molecule type, application, end use, usage type, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Mexico; South Africa; Saudi Arabia
Key companies profiled
Sartorius Stedim Biotech; Thermo Fisher Scientific; Danaher; Merck KgaA; Celltainer Biotech BV; Getinge AB; Eppendorf AG; Cellexus; PBS Biotech Inc.; Distek Inc.; ABEC; Able Corporation & Biott Corporation; G&G Technologies Inc.; Solida Biotech GmbH; Satake Chemical Equipment Mfg., Ltd.; Stobbe Pharma GmbH; bbi-biotech GmbH
Free report customization (equivalent to up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail of customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global single-use bioreactors market report on the basis of product, type, type of cell, molecule type, application, end use, usage type, and region:
Product Outlook (Revenue, USD Million, 2017 - 2028)
Single-use bioreactor systems
Up to 10L
Single-use media bags
Single-use Filtration Assemblies
Type Outlook (Revenue, USD Million, 2017 - 2028)
Type of Cell Outlook (Revenue, USD Million, 2017 - 2028)
Molecule Type Outlook (Revenue, USD Million, 2017 - 2028)
Gene Modified Cells
Application Outlook (Revenue, USD Million, 2017 - 2028)
Research and Development (R&D) or Process Development
End-use Outlook (Revenue, USD Million, 2017 - 2028)
Pharmaceutical & Biopharmaceutical Companies
CROs & CMOs
Academic & Research Institutes
Usage Type Outlook (Revenue, USD Million, 2017 - 2028)
Regional Outlook (Revenue, USD Million, 2017 - 2028)
Middle East & Africa
b. The global single-use bioreactors market size was estimated at USD 2.21 billion in 2020 and is expected to reach USD 2.73 billion in 2021.
b. The global single-use bioreactors market is expected to grow at a compound annual growth rate of 17.0% from 2021 to 2028 to reach USD 7.76 billion by 2028.
b. Single-use bioreactor systems dominated the single-use bioreactors market with a share of 82.07% in 2020. This is attributed to the various commercial advantages offered by their systems coupled with increasing adoption by end-users in the market.
b. Some key players operating in the single-use bioreactors market include Thermo Fisher Scientific, Sartorius Stedim Biotech, Danaher, Merck KgaA, Celltainer Biotech BV, Getinge AB, Eppendorf AG, Cellexus, PBS Biotech Inc., and Distek Inc.
b. Key factors that are driving the single-use bioreactors market growth include increasing adoption of SUBs among small companies and startups, reduction in automation complexity, reduction in energy and water consumption, rising research in the biopharmaceutical market, and technological advancements in SUBs.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."